Table 3 Cost-effectiveness results (cohort of 1,000 patients)
Continuous CB | Second line LC | Difference | |
|---|---|---|---|
Therapy response | |||
Number of responders in predialysis | 445 | 658 | 213 |
Number of responders in dialysis | −60 | −57 | 3 |
Total number of responders | 385 | 601 | 216 |
Health outcomes | |||
Life Years | 6,868 | 6,981 | 113 |
Dialysis free years | 0 | 108 | 108 |
QALY’s | 4,579 | 4,653 | 74 |
Costs –(€, 2013) | |||
Total costs (€ thousand) | €5,044 | €1,169 | € -3,875 |
Drug costs (€ thousand) | €468 | €1,169 | € 701 |
Dialysis costs (€ thousand) | €4,576 | €0 | |
Cost-effectiveness incremental ratio (ICER) | |||
Cost per life-year gained (€) | Dominant | ||
Cost per QALY gained (€) | Dominant | ||
Net monetary benefit (€ thousand) | €6,092 | ||